Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7607)
All Articles published online
|
Sep 21, 2010 (publication date) through Nov 21, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Liu H, Li P, Zhai Y, Qu CF, Zhang LJ, Tan YF, Li N, Ding HG. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 2010; 16(35): 4410-4415 [PMID: 20845507 DOI: 10.3748/wjg.v16.i35.4410] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v16/i35/4410.htm |
| Number | Citing Articles |
| 1 |
Arthur Zimmermann. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. 2016; : 1 doi: 10.1007/978-3-319-26587-2_3-1
|
| 2 |
Manuele Gori, Mario Arciello, Clara Balsano. MicroRNAs in Nonalcoholic Fatty Liver Disease: Novel Biomarkers and Prognostic Tools during the Transition from Steatosis to Hepatocarcinoma. BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/741465
|
| 3 |
Michele Dal Bo, Elena De Mattia, Lorena Baboci, Silvia Mezzalira, Erika Cecchin, Yehuda G. Assaraf, Giuseppe Toffoli. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates 2020; 51: 100702 doi: 10.1016/j.drup.2020.100702
|
| 4 |
Robert J. Wong, Aijaz Ahmed, Robert G. Gish. Elevated Alpha-Fetoprotein. Clinics in Liver Disease 2015; 19(2): 309 doi: 10.1016/j.cld.2015.01.005
|
| 5 |
Batchimeg Batbaatar, Unenbat Gurbadam, Odonchimeg Tuvshinsaikhan, Nyam-Erdene Narmandakh, Gerelee Khatanbaatar, Munkhbat Radnaabazar, Dulguun Erdene‑Ochir, Minjuur Boldbaatar, Munkhdelger Byambaragchaa, Yerbolat Amankyeldi, Munkhzaya Chogsom, Nyamsuren Ganbileg, Amgalantuul Batdelger, Tserendorj Demchig, Lkham Nyam‑Osor, Batsaikhan Bayartugs, Enkhtsatsral Batmunkh, Batkhishig Munkhjargal, Tulgaa Lonjid, Batbayar Khasbagana, Munkhbat Batmunkh, Sarantuya Jav, Munkhbayar Semchin. Evaluation of glypican‑3 in patients with hepatocellular carcinoma. Molecular and Clinical Oncology 2024; 22(1) doi: 10.3892/mco.2024.2796
|
| 6 |
Marina Curado Valsechi, Ana Beatriz Bortolozo Oliveira, André Luis Giacometti Conceição, Bruna Stuqui, Natalia Maria Candido, Paola Jocelan Scarin Provazzi, Luiza Ferreira de Araújo, Wilson Araújo Silva, Marilia de Freitas Calmon, Paula Rahal. GPC3 reduces cell proliferation in renal carcinoma cell lines. BMC Cancer 2014; 14(1) doi: 10.1186/1471-2407-14-631
|
| 7 |
Yukihiro Haruyama, Kenji Yorita, Tetsuji Yamaguchi, Sachiko Kitajima, Jun Amano, Toshihiko Ohtomo, Akinobu Ohno, Kazuhiro Kondo, Hiroaki Kataoka. High preoperative levels of serum glypican‐3 containing N‐terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. International Journal of Cancer 2015; 137(7): 1643 doi: 10.1002/ijc.29518
|
| 8 |
Chao-Wei Lee, Hsin-I Tsai, Wei-Chen Lee, Shu-Wei Huang, Cheng-Yu Lin, Yi-Chung Hsieh, Tony Kuo, Chun-Wei Chen, Ming-Chin Yu. Normal Alpha-Fetoprotein Hepatocellular Carcinoma: Are They Really Normal?. Journal of Clinical Medicine 2019; 8(10): 1736 doi: 10.3390/jcm8101736
|
| 9 |
Antonio Junior Lepedda, Gabriele Nieddu, Nikos Karamanos, Marilena Formato. The Extracellular Matrix and the Tumor Microenvironment. Biology of Extracellular Matrix 2022; 11: 119 doi: 10.1007/978-3-030-99708-3_6
|
| 10 |
Zhao-Shan Niu, Xiao-Jun Niu, Mei Wang. Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival. World Journal of Hepatology 2015; 7(1): 7-27 doi: 10.4254/wjh.v7.i1.7
|
| 11 |
Eric Waidely, Abdul-Rahman Obaid Al-Yuobi, A. S. Bashammakh, Mohammad S. El-Shahawi, Roger M. Leblanc. Serum protein biomarkers relevant to hepatocellular carcinoma and their detection. The Analyst 2016; 141(1): 36 doi: 10.1039/C5AN01884F
|
| 12 |
Abdelfattah M. Attallah, Mohamed El-Far, Mohamed M. Omran, Mohamed A. Abdelrazek, Ahmed A. Attallah, Aya M. Saeed, Khaled Farid. GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma. Tumor Biology 2016; 37(9): 12571 doi: 10.1007/s13277-016-5127-6
|
| 13 |
Zheng Guo, Jing Wang, Li Li, Rong Liu, Jin Fang, Bin Tie. Value of miR-1271 and glypican-3 in evaluating the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. World Journal of Clinical Cases 2020; 8(16): 3493-3502 doi: 10.12998/wjcc.v8.i16.3493
|
| 14 |
Agnieszka Lembas, Tomasz Mikuła, Magdalena Suchacz, Joanna Kozłowska, Szymon Barczak, Barbara Badura, Alicja Wiercińska-Drapało. Normal Glypican-3 Serum Levels Do Not Eliminate the Risk of Hepatocellular Carcinoma. Galician Medical Journal 2024; doi: 10.21802/e-GMJ2024-A22
|
| 15 |
Chunmei Xie, Christian Tiede, Xuanyi Zhang, Congrong Wang, Zhixiong Li, Xiao Xu, Michael J. McPherson, Darren C. Tomlinson, Weiwen Xu. Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-10083-w
|
| 16 |
Davide Busato, Monica Mossenta, Lorena Baboci, Federica Di Cintio, Giuseppe Toffoli, Michele Dal Bo. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. Expert Review of Clinical Pharmacology 2019; 12(5): 453 doi: 10.1080/17512433.2019.1598859
|
| 17 |
Arthur Zimmermann. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. 2017; : 65 doi: 10.1007/978-3-319-26956-6_3
|
| 18 |
Yu‑Xue Gao, Tong‑Wang Yang, Ji‑Ming Yin, Peng‑Xiang Yang, Bu‑Xin Kou, Meng‑Yin Chai, Xiao‑Ni Liu, De‑Xi Chen. Progress and prospects of biomarkers in�primary liver cancer (Review). International Journal of Oncology 2020; doi: 10.3892/ijo.2020.5035
|
| 19 |
Hui‐Lai Miao, Chang‐Jiang Lei, Zhi‐Dong Qiu, Zhong‐Kao Liu, Ran Li, Shi‐Ting Bao, Ming‐Yi Li. MicroRNA‐520c‐3p inhibits hepatocellular carcinoma cell proliferation and invasion through induction of cell apoptosis by targeting glypican‐3. Hepatology Research 2014; 44(3): 338 doi: 10.1111/hepr.12121
|
| 20 |
Yanyan Xia, Yuanying Zhang, Mengjiao Shen, Hongpan Xu, Zhiyang Li, Nongyue He. Golgi protein 73 and its diagnostic value in liver diseases. Cell Proliferation 2019; 52(2) doi: 10.1111/cpr.12538
|
| 21 |
Stevan A. Gonzalez, Emmet B. Keeffe. Diagnosis of Hepatocellular Carcinoma: Role of Tumor Markers and Liver Biopsy. Clinics in Liver Disease 2011; 15(2): 297 doi: 10.1016/j.cld.2011.03.012
|
| 22 |
Taofic Mounajjed, Lizhi Zhang, Tsung-Teh Wu. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms. Human Pathology 2013; 44(4): 542 doi: 10.1016/j.humpath.2012.06.016
|
| 23 |
Yukihiro Haruyama, Hiroaki Kataoka. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World Journal of Gastroenterology 2016; 22(1): 275-283 doi: 10.3748/wjg.v22.i1.275
|
| 24 |
Ovidiu Preda, Francisco F. Nogales. Pathology and Biology of Human Germ Cell Tumors. 2017; : 131 doi: 10.1007/978-3-662-53775-6_4
|
| 25 |
Anusha H. Tennakoon, Takeshi Izawa, Kavindra K. Wijesundera, Chisa Katou-Ichikawa, Miyuu Tanaka, Hossain M. Golbar, Mitsuru Kuwamura, Jyoji Yamate. Analysis of glial fibrillary acidic protein (GFAP)-expressing ductular cells in a rat liver cirrhosis model induced by repeated injections of thioacetamide (TAA). Experimental and Molecular Pathology 2015; 98(3): 476 doi: 10.1016/j.yexmp.2015.03.010
|
| 26 |
Katharina Wiedemeyer, Martin Köbel, Holly Koelkebeck, Zhan Xiao, Kapil Vashisht. High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy. Human Pathology 2020; 98: 56 doi: 10.1016/j.humpath.2020.01.002
|
| 27 |
Francisco F Nogales, Ovidiu Preda, Alina Nicolae. Yolk sac tumours revisited. A review of their many faces and names. Histopathology 2012; 60(7): 1023 doi: 10.1111/j.1365-2559.2011.03889.x
|
| 28 |
ZHIJIAN PAN, CHUNZHOU CHEN, HAOCHENG LONG, CHANGJIANG LEI, GANG TANG, LEI LI, JIARUI FENG, FEIXIANG CHEN. Overexpression of GPC3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis. Molecular Medicine Reports 2013; 7(3): 969 doi: 10.3892/mmr.2013.1279
|
| 29 |
Xiao-Fei Liu, Zhi-De Hu, Xiao-Cui Liu, Yuan Cao, Chun-Mei Ding, Cheng-Jin Hu. Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: A systematic review and meta-analysis. Clinical Biochemistry 2014; 47(3): 196 doi: 10.1016/j.clinbiochem.2013.12.007
|
| 30 |
JuanPing Yu, Qiang Ma, Bin Zhang, RuiJuan Ma, XiGuang Xu, MingSong Li, WeiWen Xu, Ming Li. Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis. Science China Life Sciences 2013; 56(3): 234 doi: 10.1007/s11427-013-4451-y
|
| 31 |
Jian Li, Sun Qiyu, Tiezheng Wang, Boxun Jin, Ning Li. Improving the Detection of Hepatocellular Carcinoma using serum AFP expression in combination with GPC3 and micro-RNA miR-122 expression. Open Life Sciences 2019; 14(1): 53 doi: 10.1515/biol-2019-0007
|
| 32 |
Mahmoud Khattab, Magdy Fouad, Elham Ahmed. Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma. World Journal of Hepatology 2015; 7(23): 2474-2481 doi: 10.4254/wjh.v7.i23.2474
|
| 33 |
Xu Yi, Li Long, Chunzhang Yang, Yingying Lu, Mingliang Cheng, Diego Calvisi. Maotai Ameliorates Diethylnitrosamine-Initiated Hepatocellular Carcinoma Formation in Mice. PLoS ONE 2014; 9(4): e93599 doi: 10.1371/journal.pone.0093599
|
| 34 |
Monica Mossenta, Davide Busato, Michele Dal Bo, Paolo Macor, Giuseppe Toffoli. Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. International Journal of Molecular Sciences 2022; 23(17): 10038 doi: 10.3390/ijms231710038
|
| 35 |
Sheng-Li Yang, Xiefan Fang, Zao-Zao Huang, Xiang-Jie Liu, Zhi-Fan Xiong, Ping Liu, Hong-Yi Yao, Chang-Hai Li. Can Serum Glypican-3 Be a Biomarker for Effective Diagnosis of Hepatocellular Carcinoma? A Meta-Analysis of the Literature. Disease Markers 2014; 2014: 1 doi: 10.1155/2014/127831
|
| 36 |
YONGLE WU, HUI LIU, HONGLEI WENG, XIN ZHANG, PENG LI, CHUN-LEI FAN, BING LI, PEI-LING DONG, LEI LI, STEVEN DOOLEY, HUI-GUO DING. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. International Journal of Oncology 2015; 46(3): 1275 doi: 10.3892/ijo.2015.2827
|
| 37 |
Tarek D. Hussein. Serological tumor markers of hepatocellular carcinoma: a meta-analysis. The International Journal of Biological Markers 2015; 30(1): 32 doi: 10.5301/jbm.5000119
|
| 38 |
Wenqing Cao, Meenal Sharma, Rami Imam, Jiangzhou Yu. Study on Diagnostic Values of Astrocyte Elevated Gene 1 (AEG-1) and Glypican 3 (GPC-3) in Hepatocellular Carcinoma. American Journal of Clinical Pathology 2019; 152(5): 647 doi: 10.1093/ajcp/aqz086
|
| 39 |
Yao Wang, Jiaxin Yang, Mei Yu, Dongyan Cao, Ying Zhang, Xuan Zong, Keng Shen. Ovarian yolk sac tumor in postmenopausal females. Medicine 2018; 97(33): e11838 doi: 10.1097/MD.0000000000011838
|
| 40 |
Gabriela Perdomo CORAL, Fernanda BRANCO, Rosalva MEURER, Patrícia dos Santos MARCON, Paulo Roberto Ott FONTES, Angelo Alves de MATTOS. RESULTS OF IMMUNOHISTOCHEMISTRY IN THE DIFFERENTIAL DIAGNOSIS OF EARLY HEPATOCELLULAR CARCINOMA AND NODULES WITH HIGH-GRADE DYSPLASIA IN PATIENTS WITH CIRRHOSIS. Arquivos de Gastroenterologia 2021; 58(1): 82 doi: 10.1590/s0004-2803.202100000-14
|
| 41 |
Cheng Xu, Zhehui Yan, Liang Zhou, Yuming Wang. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. Journal of Cancer Research and Clinical Oncology 2013; 139(8): 1417 doi: 10.1007/s00432-013-1458-5
|
| 42 |
Li Gong, Long-Xiao Wei, Pin Ren, Wen-Dong Zhang, Xiao-Yan Liu, Xiu-Juan Han, Li Yao, Shao-Jun Zhu, Miao Lan, Yan-Hong Li, Wei Zhang, Ferruccio Bonino. Dysplastic Nodules with Glypican-3 Positive Immunostaining: A Risk for Early Hepatocellular Carcinoma. PLoS ONE 2014; 9(1): e87120 doi: 10.1371/journal.pone.0087120
|
| 43 |
Iman A. Abd El Gawad, Ghada I. Mossallam, Noha H. Radwan, Heba M. Elzawahry, Niveen M. Elhifnawy. Comparing Prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins Glypican-3, Alpha feto protein and Carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients. Journal of the Egyptian National Cancer Institute 2014; 26(2): 79 doi: 10.1016/j.jnci.2014.01.001
|
| 44 |
Woo-Ri Shin, Dae-Young Park, Ji Hun Kim, Jin-Pyo Lee, Nguyen Quang Thai, In-Hwan Oh, Simranjeet Singh Sekhon, Wooil Choi, Sung Yeon Kim, Byung-Kwan Cho, Sun Chang Kim, Jiho Min, Ji-Young Ahn, Yang-Hoon Kim. Structure based innovative approach to analyze aptaprobe–GPC3 complexes in hepatocellular carcinoma. Journal of Nanobiotechnology 2022; 20(1) doi: 10.1186/s12951-022-01391-z
|
| 45 |
Xiaobo Jia, Jiao Liu, Yingtang Gao, Yong Huang, Zhi Du. Diagnosis Accuracy of Serum Glypican-3 in Patients with Hepatocellular Carcinoma: A Systematic Review with Meta-analysis. Archives of Medical Research 2014; 45(7): 580 doi: 10.1016/j.arcmed.2014.11.002
|
| 46 |
Li-Li Han, Yi Lv, Hui Guo, Zhi-Ping Ruan, Ke-Jun Nan. Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy. World Journal of Gastroenterology 2014; 20(30): 10249-10261 doi: 10.3748/wjg.v20.i30.10249
|
| 47 |
Ruben D. Houvast, Mireille Vankemmelbeke, Lindy G. Durrant, Manfred Wuhrer, Victor M. Baart, Peter J. K. Kuppen, Lioe-Fee de Geus-Oei, Alexander L. Vahrmeijer, Cornelis F. M. Sier. Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging. Cancers 2020; 12(12): 3870 doi: 10.3390/cancers12123870
|
| 48 |
Xiaoting Luo, Xin He, Xingmei Zhang, Xiaohui Zhao, Yuzhe Zhang, Yusheng Shi, Shengni Hua. Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy. MedComm 2024; 5(2) doi: 10.1002/mco2.474
|
| 49 |
Shujian Ge, Yali Xu, Hongliang Wang, Yaxin Sun, Xiangguo Tian, Zhixin Cao, Xiaoyan Lin, Jiawen Xu, Qiangxiu Wang. Downregulation of esophageal cancer-related gene 4 promotes proliferation and migration of hepatocellular carcinoma. Oncology Letters 2017; 14(3): 3689 doi: 10.3892/ol.2017.6616
|
| 50 |
Nannan Zhang, Zhenni Hu, Yong Qiang, Xiaochao Zhu. Circulating miR‐130b‐ and miR‐21‐based diagnostic markers and therapeutic targets for hepatocellular carcinoma. Molecular Genetics & Genomic Medicine 2019; 7(12) doi: 10.1002/mgg3.1012
|
| 51 |
Xiaobo Jia, Yingtang Gao, Daokuan Zhai, Jiao Liu, Junjun Cai, Yajie Wang, Li Jing, Zhi Du. Assessment of the Clinical Utility of Glypican 3 as a Serum Marker for the Diagnosis of Hepatocellular Carcinoma. Technology in Cancer Research & Treatment 2016; 15(6): 780 doi: 10.1177/1533034615605248
|
| 52 |
Shanshan Wang, Ning Chen, Yuhan Chen, Lin Sun, Li Li, Hui Liu. Elevated GPC3 level promotes cell proliferation in liver cancer. Oncology Letters 2018; doi: 10.3892/ol.2018.8754
|
| 53 |
Jyoji YAMATE. Stem cell pathology: histogenesis of malignant fibrous histiocytoma and characterization of myofibroblasts appearing in fibrotic lesions. Journal of Veterinary Medical Science 2023; 85(9): 895 doi: 10.1292/jvms.23-0225
|
| 54 |
J.A. Wertheim, H. Petrowsky, S. Saab, J.W. Kupiec-Weglinski, R.W. Busuttil. Major Challenges Limiting Liver Transplantation in the United States. American Journal of Transplantation 2011; 11(9): 1773 doi: 10.1111/j.1600-6143.2011.03587.x
|
| 55 |
Gregor Krings, Rageshree Ramachandran, Dhanpat Jain, Tsung-Teh Wu, Matthew M Yeh, Michael Torbenson, Sanjay Kakar. Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma. Modern Pathology 2013; 26(6): 782 doi: 10.1038/modpathol.2012.243
|
| 56 |
Zhen Wang, Yan-Jiang Han, Shun Huang, Meng Wang, Wen-Lan Zhou, Hong-Sheng Li, Quan-Shi Wang, Hu-Bing Wu. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET. Amino Acids 2018; 50(2): 309 doi: 10.1007/s00726-017-2517-z
|
| 57 |
Laetitia Fartoux, Thomas Decaens. Contribution of biomarkers and imaging in the management of hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology 2011; 35: S21 doi: 10.1016/S2210-7401(11)70004-3
|
| 58 |
Jian Li, Tiezheng Wang, Boxun Jin, Wenlei Li, Zhenshun Wang, Haitao Zhang, Yunjun Song, Ning Li. Diagnosis accuracy of serum glypican-3 level in patients with hepatocellular carcinoma: a systematic review with meta-analysis. The International Journal of Biological Markers 2018; 33(4): 353 doi: 10.1177/1724600818784409
|
| 59 |
Neven A. Hagag, Yasser B. M. Ali, Ahmed A. Elsharawy, Roba M. Talaat. Clinical Impact of Circulated miR-1291 in Plasma of Patients with Liver Cirrhosis (LC) and Hepatocellular Carcinoma (HCC): Implication on Glypican-3 Expression. Journal of Gastrointestinal Cancer 2020; 51(1): 234 doi: 10.1007/s12029-019-00234-9
|
| 60 |
Eman A.E. Badr, Tarek E. Korah, Ashraf Abdel Ghani, Sawsan El-Sayed, Safaa Badr. Role of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis. Alexandria Journal of Medicine 2014; 50(3): 221 doi: 10.1016/j.ajme.2014.01.002
|
| 61 |
Regina Cheuk-Lam Lo, Irene Oi-Lin Ng. Hepatocellular tumors: Immunohistochemical analyses for classification and prognostication. Chinese Journal of Cancer Research 2011; 23(4): 245 doi: 10.1007/s11670-011-0245-6
|
| 62 |
Iman Attia Abdelgawad, Ghada Ibrahim Mossallam, Noha Hassan Radwan, Heba Mohammed Elzawahry, Niveen Mostafa Elhifnawy. Can Glypican3 be Diagnostic for Early Hepatocellular Carcinoma among Egyptian Patients?. Asian Pacific Journal of Cancer Prevention 2013; 14(12): 7345 doi: 10.7314/APJCP.2013.14.12.7345
|
| 63 |
Dongsheng Gu, Yongsheng Xie, Jingwei Wei, Wencui Li, Zhaoxiang Ye, Zhongyuan Zhu, Jie Tian, Xubin Li. MRI‐Based Radiomics Signature: A Potential Biomarker for Identifying Glypican 3‐Positive Hepatocellular Carcinoma. Journal of Magnetic Resonance Imaging 2020; 52(6): 1679 doi: 10.1002/jmri.27199
|
| 64 |
Zhao-Shan Niu, Xiao-Jun Niu, Wen-Hong Wang, Jing Zhao. Latest developments in precancerous lesions of hepatocellular carcinoma. World Journal of Gastroenterology 2016; 22(12): 3305-3314 doi: 10.3748/wjg.v22.i12.3305
|
| 65 |
Randa Mohamed MA Farag, Dujana AlAyobi, Khalid A Alsaleh, Hye-Joo Kwon, Afaf EL-Ansary, Emad Anwar Dawoud. Influence of Glypican-3 as Anewly Diagnostic Biomarker in Earlydetection of Hepatocellular Carcinoma among Saudi Patients. Biomedical and Pharmacology Journal 2018; 11(4): 1789 doi: 10.13005/bpj/1550
|
| 66 |
Tushar Patel, Denise Harnois. Assessment of response to therapy in hepatocellular carcinoma. Annals of Medicine 2014; 46(3): 130 doi: 10.3109/07853890.2014.891355
|
| 67 |
Ting-Shuo Huang, Yu-Chiau Shyu, Robin Turner, Huang-Yang Chen, Pei-Jer Chen. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. Systematic Reviews 2013; 2(1) doi: 10.1186/2046-4053-2-37
|
| 68 |
Vladimír Šámal, Tomáš Jirásek, Vít Paldus, Igor Richter, Ondřej Hes. Urachal yolk sac tumor penetrating the bladder as a diagnostic challenge: a case report and review of the literature. Diagnostic Pathology 2022; 17(1) doi: 10.1186/s13000-022-01190-y
|
| 69 |
Ravikiran Tekupalli, Santosh Anand, Sowbhagya Ramachandregowda, Anupama Sindhghatta Kariyappa. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2. 2022; : 195 doi: 10.1016/B978-0-323-98807-0.00019-3
|
| 70 |
Sarwat Fatima, John M Luk, Ronnie TP Poon, Nikki P Lee. Dysregulated expression of dickkopfs for potential detection of hepatocellular carcinoma. Expert Review of Molecular Diagnostics 2014; 14(5): 535 doi: 10.1586/14737159.2014.915747
|
| 71 |
Jian Fan, Bin Lou, Wei Chen, Jie Zhang, Sha Lin, Fei-fei Lv, Yu Chen. Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest. Tumor Biology 2014; 35(11): 11523 doi: 10.1007/s13277-014-2358-2
|
| 72 |
Tarek Mohamed Kamal Motawi, Nermin Abdel Hamid Sadik, Dina Sabry, Nancy Nabil Shahin, Sally Atef Fahim. rs2267531, a promoter SNP within glypican-3 gene in the X chromosome, is associated with hepatocellular carcinoma in Egyptians. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-43376-3
|
| 73 |
Min Chen, Guohua Li, Jian Yan, Xiuzhi Lu, Jianwei Cui, Zhengxian Ni, Weizhong Cheng, Gengsun Qian, Jing Zhang, Hong Tu. Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clinica Chimica Acta 2013; 423: 105 doi: 10.1016/j.cca.2013.04.026
|
| 74 |
Jia-Mei Dong, Rui-Qi Wang, Ning-Ning Yuan, Jia-Hao Guo, Xin-Yang Yu, Ang-Hui Peng, Jia-Yi Cai, Lei Xue, Zhi-Ling Zhou, Yi-Hao Sun, Ying-Yin Chen. Recent advances in optical aptasensors for biomarkers in early diagnosis and prognosis monitoring of hepatocellular carcinoma. Frontiers in Cell and Developmental Biology 2023; 11 doi: 10.3389/fcell.2023.1160544
|
| 75 |
Yunsheng Zhao, Qin Gao, Liu Pei, Chunhua Wang, Liang Jin, Fei Liao. Current Status and Future Prospects of Biomarkers in the Diagnosis of Hepatocellular Carcinoma. The International Journal of Biological Markers 2017; 32(4): 361 doi: 10.5301/ijbm.5000299
|
| 76 |
Dahai Xu, Chang Su, Liang Sun, Yuanyuan Gao, Youjun Li. Performance of Serum Glypican 3 in Diagnosis of Hepatocellular Carcinoma: A meta-analysis. Annals of Hepatology 2019; 18(1): 58 doi: 10.5604/01.3001.0012.7863
|
| 77 |
Hyun Jung Lee, Jong Eun Yeon, Sang Jun Suh, Sun Jae Lee, Eileen L. Yoon, Keunhee Kang, Yang Jae Yoo, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Kwan Soo Byun. Clinical Utility of Plasma Glypican-3 and Osteopontin as Biomarkers of Hepatocellular Carcinoma. Gut and Liver 2014; 8(2): 177 doi: 10.5009/gnl.2014.8.2.177
|
| 78 |
Hui‐Lai Miao, Zhi‐Jian Pan, Chang‐Jiang Lei, Ji‐Yu Wen, Ming‐Yi Li, Zhong‐Kao Liu, Zhi‐Dong Qiu, Man‐Zhou Lin, Nian‐Ping Chen, Ming Chen. Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down‐regulation of YAP. Journal of Cellular Biochemistry 2013; 114(3): 625 doi: 10.1002/jcb.24404
|
| 79 |
Tsung-Chieh Shih, Lijun Wang, Hsiao-Chi Wang, Yu-Jui Yvonne Wan. Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma. Liver Research 2020; 4(4): 168 doi: 10.1016/j.livres.2020.11.003
|
| 80 |
Alessandra Tessitore, Germana Cicciarelli, Filippo Del Vecchio, Agata Gaggiano, Daniela Verzella, Mariafausta Fischietti, Valentina Mastroiaco, Antonella Vetuschi, Roberta Sferra, Remo Barnabei, Daria Capece, Francesca Zazzeroni, Edoardo Alesse. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice. BMC Cancer 2016; 16(1) doi: 10.1186/s12885-015-2007-1
|
| 81 |
Agostino Colli, Tin Nadarevic, Damir Miletic, Vanja Giljaca, Mirella Fraquelli, Davor Štimac, Giovanni Casazza. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database of Systematic Reviews 2021; 2021(4) doi: 10.1002/14651858.CD013346.pub2
|
| 82 |
Zhejia Zhang, Linyong Xu, Zhiming Wang. Screening serum biomarkers for early primary hepatocellular carcinoma using a phage display technique. Journal of Clinical Laboratory Analysis 2011; 25(6): 402 doi: 10.1002/jcla.20491
|
| 83 |
Ming-Chin Yu, Yun-Shien Lee, Sey-En Lin, Hsiang-Yao Wu, Tse-Ching Chen, Wei-Chen Lee, Miin-Fu Chen, Chi-Neu Tsai. Recurrence and Poor Prognosis Following Resection of Small Hepatitis B-Related Hepatocellular Carcinoma Lesions Are Associated with Aberrant Tumor Expression Profiles of Glypican 3 and Osteopontin. Annals of Surgical Oncology 2012; 19(S3): 455 doi: 10.1245/s10434-011-1946-2
|